Illumina Officials Say Array Business Will Benefit from Epicentre Buy

CEO Jay Flatley said Illumina has in the past licensed "several" Epicentre enzymes for use in its array business. Now the company has the "ability to use those enzymes at cost rather than [retail] price."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories